Advertisement
GKOS vs ISRG
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- GKOS is a specialized ophthalmic medical technology company focused on micro-invasive glaucoma surgery (MIGS), while ISRG dominates the robotic-assisted surgery market with its da Vinci surgical systems.
- Both stocks operate in the high-growth medical technology sector, but ISRG represents a more mature, profitable business model, whereas GKOS is still navigating the path toward consistent profitability.
- Recent market activity shows divergent momentum patterns, with ISRG demonstrating steadier institutional accumulation and GKOS experiencing more pronounced volatility linked to clinical trial milestones and reimbursement developments.
- Revenue growth remains a bright spot for both companies, though their scale differs dramatically — ISRG generates billions in annual revenue while GKOS operates at a much earlier stage of commercial expansion.
- Investor sentiment around GKOS has been shaped by its expanding product pipeline in corneal health and sustained MIGS adoption, while ISRG benefits from rising procedure volumes and installed base growth of its robotic platforms globally.
Introduction
Comparing GKOS and ISRG offers a compelling lens into two very different stages of medtech leadership. Glaukos Corporation has carved out a niche in ophthalmic surgical innovation — specifically in glaucoma and corneal disorders — while Intuitive Surgical has built a dominant, multi-decade franchise in robotic-assisted minimally invasive surgery. This comparison is especially relevant for growth-oriented investors and traders evaluating the risk-reward profile of an emerging disruptor versus an established category leader. Both companies benefit from secular tailwinds in surgical innovation, yet their market positioning, financial maturity, and volatility characteristics present distinct trade-offs worth examining in the current market environment.
GKOS Overview and Recent Performance
GKOS, or Glaukos Corporation, is a medical technology company specializing in therapies for glaucoma, corneal disorders, and retinal diseases. Its flagship iStent family of micro-invasive glaucoma surgery (MIGS) devices has been a key growth engine, and the company continues to expand into the corneal health market with products like Photrexa. In recent weeks, market attention has focused on Glaukos's broader pipeline progression, including its iDose TR sustained-release implant and several late-stage clinical programs targeting unmet ophthalmic needs.
Share price behavior in recent months has reflected a mix of clinical optimism and reimbursement-related uncertainty. Glaukos has posted strong double-digit revenue growth on a year-over-year basis, driven by MIGS procedure volume expansion and rising adoption among ophthalmic surgeons. However, profitability remains elusive as the company continues to invest heavily in research and development (R&D) and commercial infrastructure. The stock has experienced bouts of elevated volatility, particularly around earnings releases and Medicare coverage determinations that directly affect procedure reimbursement for its devices. Institutional ownership trends and analyst revisions have generally leaned constructive, though the stock's valuation — which often trades at a premium revenue multiple relative to the broader medtech sector — leaves limited room for execution missteps.
ISRG Overview and Recent Performance
ISRG, or Intuitive Surgical, Inc., is the global leader in robotic-assisted minimally invasive surgery, best known for its da Vinci surgical systems. The company generates revenue through a razor-and-blade model: selling robotic systems to hospitals and healthcare facilities, then earning recurring income from instruments, accessories, and service contracts as procedure volumes grow. With an installed base of thousands of da Vinci systems worldwide, Intuitive has established formidable competitive moats rooted in surgeon training ecosystems, clinical data libraries, and high switching costs.
Recent market activity indicates continued momentum for ISRG, underpinned by recovering surgical procedure volumes and growing adoption of robotic-assisted techniques across general surgery, gynecology, urology, and thoracic procedures. The company has consistently delivered solid revenue growth, robust gross margins exceeding 65%, and strong free cash flow generation. In recent weeks, analysts have focused on Intuitive's international expansion efforts, particularly in Asia and Europe, as well as the rollout of next-generation platforms such as the da Vinci 5 (dV5). Unlike GKOS, ISRG benefits from a well-established profitability profile and a fortress-like balance sheet, which tends to attract steadier institutional capital flows and lower relative volatility during risk-off market episodes.
Trending AI Robots
For traders who prefer a data-driven approach to navigating stock comparisons like this one, Tickeron's Trending AI Robots page offers access to a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers across diverse market conditions, but only a small fraction earn placement in this exclusive section. These top-performing bots are selected based on real-time statistical merit and their suitability to current market dynamics. Each bot operates with its own trading style, strategy, timeframe, and risk profile — some targeting short-term swing trades, others focused on longer-duration momentum or value rotations. Performance metrics such as annualized returns and win rates vary across bots, giving users the ability to evaluate alignment with their personal trading objectives. Explore the Trending AI Robots page to discover which automated strategies are currently resonating with the market.
Head-to-Head Comparison
From a business model perspective, the contrast between GKOS and ISRG is stark. Intuitive Surgical operates a mature, diversified franchise with recurring revenue streams, global scale, and GAAP (Generally Accepted Accounting Principles) profitability measured in the billions. Glaukos, by comparison, is still in a high-investment growth phase where operating losses are the norm as it builds out commercial scale and funds an ambitious pipeline. This translates directly into risk profiles: ISRG tends to exhibit lower beta and steadier price action, while GKOS can swing sharply on binary catalysts such as FDA (U.S. Food and Drug Administration) decisions or Medicare coverage rulings.
Growth drivers also differ meaningfully. GKOS is levered to the relatively underpenetrated MIGS market and the emerging corneal cross-linking opportunity, representing potentially large total addressable markets with significant expansion runway. ISRG's growth is tied to broader surgical robotics adoption, procedure volume trends, and hospital capital expenditure cycles — more predictable in aggregate but measured against a much larger base. In terms of recent relative performance, both stocks have benefited from favorable healthcare utilization trends, though ISRG has demonstrated greater resilience during broader market pullbacks. Risk factors for GKOS center on regulatory and reimbursement policy shifts, while ISRG faces competitive threats from emerging surgical robotics entrants and pricing pressure on capital equipment. Both companies are well-positioned within the medical technology sector, but their investment profiles appeal to fundamentally different risk appetites.
Tickeron AI Verdict
Based on observable market data and trend consistency metrics, Tickeron's AI analytical framework would likely find a more favorable risk-adjusted setup in ISRG under current market conditions. ISRG's combination of sustained procedure volume growth, strong free cash flow generation, and lower relative volatility suggests a steadier trend profile — a characteristic that AI-driven models often weigh favorably when evaluating consistency and downside stability. That said, GKOS presents higher upside potential tied to pipeline catalysts and market penetration, which could be appealing for shorter-duration, momentum-oriented AI strategies operating with higher risk tolerance. The probabilistic assessment tilts toward ISRG for stability-focused algorithms, while GKOS may capture attention from bots tuned to volatility and catalyst-driven price action. Neither conclusion constitutes a prediction, but rather a structured evaluation of how each stock's observable characteristics align with different AI-driven trading frameworks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a StrongBuy and ISRG is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- GKOS’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 4 TA indicator(s) are bullish while ISRG’s TA Score has 6 bullish TA indicator(s).
- GKOS’s TA Score: 4 bullish, 4 bearish.
- ISRG’s TA Score: 6 bullish, 3 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а +8.56% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +4.69% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
GKOS is expected to report earnings on Nov 04, 2026.
ISRG is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| GKOS | ISRG | GKOS / ISRG | |
| Capitalization | 9.83B | 125B | 8% |
| EBITDA | -141.49M | 4.25B | -3% |
| Gain YTD | 47.657 | -37.614 | -127% |
| P/E Ratio | N/A | 40.52 | - |
| Revenue | 613M | 11B | 6% |
| Total Cash | 286M | 5.22B | 5% |
| Total Debt | 103M | 87M | 118% |
GKOS | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 49 | 89 | |
SMR RATING 1..100 | 98 | 51 | |
PRICE GROWTH RATING 1..100 | 36 | 64 | |
P/E GROWTH RATING 1..100 | 59 | 90 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (70) in the Medical Specialties industry is in the same range as GKOS (95). This means that ISRG’s stock grew similarly to GKOS’s over the last 12 months.
GKOS's Profit vs Risk Rating (49) in the Medical Specialties industry is somewhat better than the same rating for ISRG (89). This means that GKOS’s stock grew somewhat faster than ISRG’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for GKOS (98). This means that ISRG’s stock grew somewhat faster than GKOS’s over the last 12 months.
GKOS's Price Growth Rating (36) in the Medical Specialties industry is in the same range as ISRG (64). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
GKOS's P/E Growth Rating (59) in the Medical Specialties industry is in the same range as ISRG (90). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
| GKOS | ISRG | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 77% | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 70% | 3 days ago 65% |
| Momentum ODDS (%) | 3 days ago 85% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 85% | 3 days ago 66% |
| TrendWeek ODDS (%) | 3 days ago 79% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 77% | 3 days ago 70% |
| Advances ODDS (%) | 4 days ago 78% | 6 days ago 66% |
| Declines ODDS (%) | 6 days ago 68% | 4 days ago 61% |
| BollingerBands ODDS (%) | 3 days ago 80% | 3 days ago 77% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 71% |
Advertisement
GKOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To GKOS | 1D Price Change % | ||
|---|---|---|---|---|
| GKOS | 100% | -1.07% | ||
| ISRG - GKOS | 51% Loosely correlated | +0.10% | ||
| NTRA - GKOS | 48% Loosely correlated | -0.70% | ||
| RDNT - GKOS | 48% Loosely correlated | +1.74% | ||
| TWST - GKOS | 46% Loosely correlated | +0.24% | ||
| ALGN - GKOS | 43% Loosely correlated | -2.45% | ||
More | ||||